Preformulation Study of an Antipsychotic Drug Aripiperazole

Aripiperazole is an atypical antipsychotic belongs to BCS Class IV, hygroscopic drug used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder also helps to balance dopamine and serotonin levels in the brain with potentially fewer side effects like weight gain. So It has low risk of hyperprolactemia and lower incidence of sedation, Due to this reason doctors and patients often prefer it This comprehensive preformulation study aims to investigate the physicochemical properties of aripiprazole and evaluate its behavior under various conditions relevant to pharmaceutical formulation development. To understand its physical and chemical properties to develop a safe effective and stable dosage form using this drug aripiperazole. Its preformulation study is require. The preformulation study encompasses solubility analysis, stability assessment, particle size distribution, polymorphism, hygroscopicity, and compatibility with common excipients e.g Magnesium stearate, Polyvinyl pyrollidone K30, Lactose monohydrate, Microcrystalline cellulose. Results indicate that aripiprazole exhibits poor aqueous solubility, with pH-dependent solubility profiles. Stability studies reveal sensitivity to light and elevated temperatures. Particle size analysis shows a tendency for agglomeration, while polymorphic studies confirm the existence of multiple crystal forms. Hygroscopicity tests demonstrate minimal moisture uptake under standard conditions. Excipient compatibility studies identify potential interactions with certain additives like Magnesium stearate and Polyvinyl pyrollidone K30 exhibiting a conclusion that during formulation aripiperazole needs special attention and care as well standard optimization studies which can be proved as useful side effect reduction. These findings provide crucial insights for the development of stable, effective formulations of aripiprazole, paving the way for improved drug delivery systems and therapeutic outcomes.